Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Arrow is the marketing partner in US
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)